19:27 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

CPS1 protein to treat drug-induced liver toxicity

DISEASE CATEGORY: Hepatic INDICATION: Drug-induced liver toxicity (DILI) Mouse studies suggest CPS1 could help treat DILI. In a mouse model of FASL-induced liver toxicity, CPS1 decreased serum levels of alanine transaminase (ALT), a marker of...
14:23 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting FASL for ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting FASL could help treat ischemic stroke. In a mouse model of middle cerebral artery occlusion (MCAO)-induced stroke, an anti-FASL mAb decreased ischemic brain injury and levels...
01:13 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest FASL inhibitors could help treat immunotherapy-resistant melanoma. In a mouse model of immunotherapy-resistant melanoma, a fusion protein consisting of Fas receptor and the Fc region of murine IgG2A (Fas-Fc) that...
22:43 , Nov 16, 2017 |  BC Extra  |  Preclinical News

FAS/FASL pathway involved in immunotherapy resistance

A study published in Nature Communications by researchers at the Ludwig Institute for Cancer Research and colleagues identified Fas ligand (TNF superfamily, member 6; FASL) as a potential target to overcome resistance to cancer immunotherapy...
21:50 , Apr 20, 2017 |  BC Week In Review  |  Clinical News

ApoGraft: Ph I/II ApoGraft01 ongoing

An independent DSMB approved the enrollment of the next 2 patients in the first cohort of the open-label, Israeli Phase I/II ApoGraft01 trial evaluating transplanted ApoGraft exposed to FASL. The DSMB made the recommendation after...
21:56 , Feb 9, 2017 |  BC Week In Review  |  Clinical News

ApoGraft: Ph I/II started

Cellect began an open-label, Israeli Phase I/II trial to evaluate transplanted ApoGraft exposed to 10, 25, 50 or 100 ng/mL FASL in about 12 patients undergoing allogeneic stem cell transplantation (ASCT) from a matched related...
21:07 , Dec 2, 2016 |  BC Week In Review  |  Company News

Cellect, Hadassah deal

Hadassah's Hadasit Ltd. technology transfer arm partnered with Cellect to conduct preclinical studies of Cellect’s ApoGraft to treat graft-versus-host disease (GvHD). Hadassah will conduct the studies. ApoGraft consists of mobilized peripheral blood cells (MPBC) for...
08:00 , Jan 28, 2016 |  BC Innovations  |  Tools & Techniques

Peer pressure

Research from the National Cancer Institute (NCI) suggests adoptive immunotherapies are compromised by the fact that naïve T cells are pushed to mature too fast by fully differentiated T cells in the same culture, which...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Fas ligand (TNF superfamily, member 6)(FASL)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting FASL could help improve the efficacy of adoptive T cell therapy in cancer by disrupting interactions between naïve and mature T cells. In co-cultures of...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fas ligand (TNF superfamily, member 6; FASL); VEGF-A; cyclooxygenase (COX) Mouse studies suggest inhibiting FASL could improve the efficacy of T cell-based cancer therapies....